Regeneus Presentation - FNN Investor Event

Thursday, 16 May 2019

Key points:

A clinical-stage regenerative medicine company

Portfolio of innovative cellular therapies

These target significant unmet medical needs with a licence-driven strategy

Focus on osteoarthritis and other musculoskeletal disorders

Focus on neuropathic pain and dermatology

Lead drug in knee osteoarthritis (US$5 billion addressable market)